Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on …